MIG‐6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple‐negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MIG‐6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple‐negative breast cancer

Published:2021-03-03 Issue:5 Volume:22 Page:
ISSN:1469-221X
Container-title:EMBO reports
language:en
Short-container-title:EMBO Reports

Author:

He Jiabei¹^ORCID,Li Chien‐Feng²³^ORCID,Lee Hong‐Jen¹,Shin Dong‐Hui¹,Chern Yi‐Jye¹^ORCID,Pereira De Carvalho Bruno¹,Chan Chia‐Hsin¹⁴^ORCID

Affiliation:

1. Department of Pharmacological Sciences Stony Brook University Stony Brook NY USA

2. National Institute of Cancer ResearchNational Health Research Institutes Tainan Taiwan

3. Department of Pathology Chi‐Mei Foundational Medical Center Tainan Taiwan

4. Stony Brook Cancer Center Stony Brook University Stony Brook NY USA

Funder

National Cancer Institute

Susan G. Komen

Ministry of Science and Technology, Taiwan

Health Promotion Administration, Ministry of Health and Welfare

Publisher

EMBO

Subject

Genetics,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/embr.202050781

Reference52 articles.

1. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

2. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity

3. Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine

4. Comprehensive molecular portraits of human breast tumours

5. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reprogramming of glucose metabolism: The hallmark of malignant transformation and target for advanced diagnostics and treatments;Biomedicine & Pharmacotherapy;2024-09

2. Next-generation biomarkers for prognostic and potential therapeutic enhancement in Triple negative breast cancer;Critical Reviews in Oncology/Hematology;2024-09

3. USP7 deubiquitinates epigenetic reader ZMYND8 to promote breast cancer cell migration and invasion;Journal of Biological Chemistry;2024-09

4. HSPA12A acts as a scaffolding protein to inhibit cardiac fibroblast activation and cardiac fibrosis;Journal of Advanced Research;2024-01

5. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF;JCI Insight;2023-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3